Peter Menziuso Named EVP and President, BD Interventional

FRANKLIN LAKES, N.J., May 18, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Peter Menziuso has been named executive vice president and president, BD Interventional, effective June 1.

PRNewsWire • May 18, 2026

These 5 Stocks Have 50 Years of Dividend Growth—Here's How to Find More

With a new presidential administration set to take office on Jan. 20, 2025, some investors may be uncertain about how new policies and personnel will affect the stock market and interest rates. Will tariffs, discarded trade deals, and frayed alliances help or hurt the market?

Investopedia • May 18, 2026

AI, Robotics Key to Transforming Health Care: BD CEO

Tom Polen, CEO of medical technology company BD, says that in the next decade AI and robotics will transform health care in ways that will make today's system seem archaic. Polen sits down with Bloomberg's Caroline Hyde on the sidelines of the Consello Spark Summit.

Bloomberg Technology • May 15, 2026

Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 12, 2026

Becton, Dickinson and Company Q2 Earnings Call Highlights

Becton, Dickinson and Company NYSE: BDX reported fiscal second-quarter revenue and adjusted earnings ahead of its internal expectations, while management raised its full-year adjusted earnings outlook and said growth was broad-based across most of the portfolio.

MarketBeat • May 9, 2026

Becton Dickinson raises annual profit forecast on strength in drug delivery devices

Becton Dickinson raised its annual profit forecast on Thursday, riding strong demand for its drug-delivery devices and surgical equipment, and appointed Vitor ​Roque as its chief financial officer.

Reuters • May 7, 2026

BD Stock Up in Pre-Market Post Q2 Earnings & Revenue Beat, Margins Up

BDX beats second-quarter fiscal 2026 earnings and revenue estimates, driven by broad segment strength and improved profitability.

Zacks Investment Research • May 7, 2026

Becton, Dickinson and Company (BDX) Q2 2026 Earnings Call Transcript

Becton, Dickinson and Company (BDX) Q2 2026 Earnings Call Transcript

Seeking Alpha • May 7, 2026

BD Reports Second Quarter Fiscal 2026 Financial Results

Revenue of $4.7 billion increased 5.2% as reported, 2.6% FXN GAAP and adjusted diluted EPS from continuing operations of $(0.13) and $2.90, respectively Executed a $2.0 billion accelerated share repurchase (ASR) program and retired $2.1 billion of debt in the quarter Company reaffirms revenue growth guidance, raises full-year adjusted diluted EPS guidance1 FRANKLIN LAKES, N.J., May 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 second quarter, which ended March 31, 2026.

PRNewsWire • May 7, 2026

BD Appoints Vitor Roque Chief Financial Officer

FRANKLIN LAKES, N.J., May 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Vitor Roque has been named executive vice president and chief financial officer (CFO), effective May 7.

PRNewsWire • May 7, 2026